Last reviewed 2026-04-20 · How we verify

Pholescutol (FOLESCUTOL)

Phase 2 active Small molecule

Pholescutol (generic name: FOLESCUTOL) is a drug. It is currently in Phase 2 development.

Pholescutol is a small molecule that binds to a specific target, altering its function to produce a therapeutic effect.

Pholescutol (FOLESCUTOL) is a small molecule modality developed by an unknown entity, currently owned by an unknown entity. Its target and drug class are unknown, and it has not been approved by the FDA for any indications. The commercial status of Pholescutol is unclear, and it is not known whether it is patented or available as a generic. Further information on its pharmacokinetic properties, such as half-life and bioavailability, is also unavailable. As a result, key safety considerations and potential side effects are unknown.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FOLESCUTOL
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and Pholescutol is a key that fits into one of those locks. When it binds, it changes the way the lock works, which can help to treat a particular disease or condition. This is a simplified explanation of how Pholescutol works at a molecular level.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Pholescutol CI brief — competitive landscape report
Pholescutol updates RSS · CI watch RSS

Frequently asked questions about Pholescutol

What is Pholescutol?

Pholescutol (FOLESCUTOL) is a Small molecule drug.

How does Pholescutol work?

Pholescutol is a small molecule that binds to a specific target, altering its function to produce a therapeutic effect.

What is the generic name of Pholescutol?

FOLESCUTOL is the generic (nonproprietary) name of Pholescutol.

What development phase is Pholescutol in?

Pholescutol is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing